"Magnitude Biosciences helped us with environmental toxicity studies looking at the health impact of plastic nanoparticles. The team were great to work with: they were very responsive in their communication, provided plenty of discussion and expert guidance to optimize the study design and timely answered our research questions. They impressed us with the quality of their science at every stage of the project. We were worried that the pandemic may slow progress with the experiments, but Magnitude Biosciences were set up to work very quickly and ensured the study was conducted not only very efficiently but also to a very high standard"
Dr. Natascia Ventura, MD, PhD, Group Leader, Institute of Clinical Chemistry and Laboratory Diagnostic, Medical Faculty, Heinrich Heine University
''The team at Magnitude Biosciences revealed the power of the C. elegans system in the early stages of drug development. They made us aware of the possibility and merit of using a variety of transgenics techniques in C. elegans to test the positive effects of peptides in models of neurodegeneration. We hope there will be future opportunities to partner with Magnitude Biosciences to help us develop the next generation of therapies."
Dr Penny Hayward, Principal Scientist, PhoreMost Ltd. PhoreMost has developed the protein interference SITESEEKER® platform to drug the undruggable in oncology and ageing.
''Magnitude were very collaborative, efficient and flexible as the experiments progressed. We were impressed with the power of the automated imaging technology and the speed at which we obtained the results which helped us to efficiently prioritise key compounds.''
Dr Peter Hamley, CSO, Samsara Therapeutics - Samsara is a company discovering new medicines for healthy ageing
"Magnitude Biosciences helped us with a very complex gene-editing project. We really appreciated working with their team – in particular, Michael Fasseas, who was extremely helpful with all aspects of the project, from CRISPR design through to injection/screening. Even though the project was not straightforward, they went above and beyond to adapt the project design as needed and their flexibility, responsiveness and transparency of communication, and the transgenics and C. elegans expertise they have in their team gave us a lot of confidence. We highly recommend their services as a contract C. elegans lab."
Alan Morgan, Professor of Physiology at the University of Liverpool
"It was absolutely great to work with Magnitude Biosciences on several projects involving generating extra-chromosomal transgenic lines. They are very talented at gonadal micro-injections, even difficult ones, requiring co-injection of several constructs in neurons. They were able to advise me on the best concentrations to use, based the experience of their expert team and I have been impressed at how fast and efficient they are at what they do. I would totally recommend their services as a contract lab for C. elegans research."
Laetitia Chauve, Postdoctoral Researcher, Babraham Institute, Cambridge, UK
''Pleased with the professional, efficient level of service we received from Magnitude Biosciences. We were happy to see reproducible and consistent data that has real potential for future screening projects.''
Dr Jennifer Tullet, Senior Lecturer, University of Kent.
''I am impressed by the potential of the Healthspan Machine to increase the throughput of C. elegans assays.''
Liping Zhao, Rutgers University
''Magnitude is an invaluable partner allowing us to test our autophagy-related drugs in an unbiased and sensitive healthspan assay in vivo.''
Dr. Viktor Korolchuk, Institute for Cell & Molecular Biosciences and Institute for Ageing, Newcastle University.
''Improving healthspan is my vision. Magnitude Biosciences provide a great tool to do it.''
Prof Thomas von Zglinicki, Newcastle University.
''Thank you so much for your professionalism. It has been a great experience to working with you on this project.''
Dr Evandro Fang, University of Oslo.